Puma Q3 2026 earnings release lacks details; thesis unchanged pending actuals

What happened

Puma Biotechnology issued a press release on November 5, 2026 announcing third quarter 2026 results and a subsequent conference call, but the release contains no financial figures or operational metrics. The DeepValue report had already flagged critical uncertainties for 2026: whether NERLYNX net product revenue can hold near $195–205M, whether Chinese royalties recover from Q3 2025's collapse from $24.4M to $2.6M, and how gross-to-net deductions trend after jumping to 25.9%. The report assigned a WAIT rating with an attractive entry below $5.25 and a trim threshold above $8.00, based on probabilities of 50% base ($6.50 implied value), 30% bear ($4.50), and 20% bull ($9.00). Without actual numbers, investors cannot determine which scenario is materializing, and the press release itself is essentially content-free marketing. The key events to watch are the detailed 10-Q filing and management commentary on conference call, particularly around pipeline progress for alisertib and covenant compliance.

Implication

If the actual Q3 2026 results confirm the base case of stable NERLYNX revenue ($195–205M), royalties recovering to ~$15M annually, and EBITDA margin ~25%, the stock is likely fairly valued around $6.65 and the WAIT rating stands. A bearish print—NERLYNX revenue below $185M, royalties still low single-digit millions, or gross-to-net above 25%—would validate the bear scenario and could push shares toward $4.50, warranting position reduction or exit. Conversely, a bullish outcome—NERLYNX above $210M, royalties above $25M, and positive interim alisertib data—would support the bull case and could drive re-rating toward $9.00. The report's specific thresholds are trim above $8.00, add below $5.25, and reassess in 12–18 months; no action is recommended absent concrete data. Investors should scrutinize the 10-Q for covenant headroom, liquidity, and any changes to alisertib timelines, as these are the primary risk factors.

Thesis delta

The announcement of Q3 2026 results does not alter the investment thesis because the press release provides no substantive financial or pipeline data. The core debate remains whether Puma can sustain NERLYNX revenue and generate value from alisertib amid rising gross-to-net pressure and volatile royalties. We retain the WAIT rating and require actual results to determine if the base, bear, or bull scenario is playing out.